

Neothetics (NEOT : US\$8.88)

Neothetics jumps 21% in 2015, outperforming 82% of its global peers

Neothetics, Inc., jumped US\$1.52 (or 20.7%) year to date in 2015 to close at US\$8.88. The stock has a 6-month USD relative strength of 82 which means in USD terms it is outperforming 82% of its 45,018 global peers. A price rise combined with a high relative strength is a bullish signal. Compared with the NASDAQ-100 Index which has risen 3.9% YTD, this is a relative price increase of 16.7%. The average daily volume of 57,066 shares so far in 2015 was 0.9 times the average daily volume in 2014. In 2015 the market cap has jumped US\$20.7 million.

Fig 1: Stock Summary

Sector	Total Nasdaq Market
Market Cap	US\$120.9 million
Shares Outstanding	13,620,148
PermID	1-4297632572
Relative Strength (3 mo)	83

Fig 2: MCap - A Historical Perspective

	Price	MCap (US\$ M)
Last	US\$8.88	120.9

Fig 3: Rank in American Region out of 12,368 stocks

Description	Value	Rank	Quartile
MCap (US\$)	120.9M	4921	Second
PV\$1000 (1Year) US\$	634.3	6698	Third
US\$ Change (1Year) %	-36.6	6510	Third
Rel Strength 6 Mo (US\$)	89	1381	Top

Fig 4: Turnover Rate & Turnover Period




Fig 5: Trailing 3 months

Turnover	US\$38.2 million
Volume	5,162,778
Volume Index (1 is avg)	1.4

Fig 6: Weekly Price Volume Dynamics (Last 12 Weeks)




Fig 7: Relative Strength




Fig 8: Price/Moving Avg Price [P/MAP200]



Fig 9: Price Change %

Price Change %	Trailing Qtr	Trailing Yr	Tr 3 Yrs
NEOT	15.78	-36.57	
Total Nasdaq Market	4.1	-2.9	45.28
NASDAQ-100 index	2	14.21	68.08

Fig 10: Shareholder Returns

Trailing quarter: The stock rose 31 times (49.2% of the time), fell 30 times (47.6% of the time) and was unchanged 2 times (3.2% of the time). The aggregate volume was 1.4 times average trading of 5.4 million shares. The value of US\$1,000 invested 3 months ago is US\$1,158 [vs 1,020 for the NASDAQ-100 Index] for a capital gain of US\$158.

Trailing 12 months: The value of US\$1,000 invested a year ago is US\$634 [vs 1,157 for the NASDAQ-100 Index] for a capital loss of US\$366.

PVUS\$1,000	Trailing Qtr	Trailing Yr	Trailing 3 Yrs
NEOT	US\$1,158	US\$634	
Total Nasdaq Market	1,041	971	1,453
NASDAQ-100 Index	1,020	1,157	1,681

Fig 11: Stock v Index (Trailing Year)




Fig 12: Month-on-Month Comparison (Trailing Month - ended 30th)

	30 Jun	29 May	30 Apr	31 Mar	27 Feb	30 Jan
Price 30 Jun (USD)	8.88	6	6.94	8.16	6.7	6.64
% Price Change	40.7	-19.7	-15	22.5	-2.5	-3.4
Avg Daily Volume	59,600	48,907	51,352	42,381	36,395	42,564
VWP (USD)	7.41	7.49	7.62	7.35	7.59	7.76
Price Range (USD)	6.05 - 8.99	5.92 - 7.65	6.27 - 9.05	6.58 - 8.88	6.42 - 7.04	6.42 - 7.59
Relative Price Change %	43.2	-20.1	-16.8	24.9	-9.1	-0.3
Volatility %	48.6	29.2	44.3	35	9.7	18.3

Fig 13: Price Volume Trend: Trailing Quarter


Fig 14: Fibonacci Retracement



Company Overview

Activities

Neothetics, Inc. is a clinical-stage pharmaceutical company. The Company develops therapeutics for the aesthetic market. The Company is focused is on localized fat reduction and body contouring.

Further details can be found at <http://www.neothetics.com>.

Ranking

Neothetics, Inc. is placed 1906/2394 in BSS News Bites' ranking of NASDAQ performers in the past year, a percentile ranking of 16%.

Sector Sorting

For Company searches, or for sorting by stocks and variables, an interactive version of today's Table is available [here](#)

8-K other news

May 14: Neothetics: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1618835_000156459015004238_0001564590-15-004238.txt

Source: 8-K United States Securities and Exchange Commission

March 26: Neothetics: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1618835_000156459015001989_0001564590-15-001989.txt

Source: 8-K United States Securities and Exchange Commission

January 21: Neothetics: Entry into a Material Definitive Agreement

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1618835_000119312515016052_0001193125-15-016052.txt

Source: 8-K United States Securities and Exchange Commission

Issued Capital


Based on 13,620,148 issued equity shares the market capitalisation is US\$120.9 million.

The top seventeen shareholders hold 16.6% of the issued capital leaving a float of 83.4%.

Fig 15: Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Clifton Park Capital Management Llc	821,566	6.03
Piper Jaffray & Co.	303,420	2.23
Federated Investors Inc /Pa/	275,400	2.02
Dafna Capital Management Llc	186,807	1.37
Lombard Odier Asset Management (Usa) Corp	179,300	1.32
Nicholas Investment Partners Lp	118,012	0.87
Alyeska Investment Group L.P.	102,724	0.75
UBS Oconnor Llc	66,698	0.49
Goldman Sachs Group Inc	56,782	0.42
Vanguard Group Inc	50,100	0.37
Total	2,160,809	15.86

Fig 16: Top 17 Institutional Holdings




Board and Management



George Mahaffey
CEO & President & Director

Mr. Mahaffey has 24 years of pharmaceutical and biotechnology industry experience. Most recently, he served as CEO of Peplin, Inc. after the dermatology company's acquisition by LEO Pharma A/S in 2014; he was instrumental in this \$287.5M transaction. Prior to the acquisition, he served as Peplin's Chief Commercial Officer and VP, Sales and Marketing. Mr. Mahaffey also served as Sr. VP, Sales and Marketing for CoTherix, Inc. where he led the corporate commercialization and successful launch of Ventavis® (iloprost), an orphan drug to treat Pulmonary Arterial Hypertension. He was heavily involved in the acquisition of CoTherix by Actelion Ltd. for \$420M in 2006. Prior to CoTherix, Mr. Mahaffey worked at Scios, Inc. (acquired by Johnson & Johnson for \$2.4B in 2003) where he led the launch of Natrecor® (nesiritide) to treat acutely decompensated congestive heart failure that proved to be one of the most successful launches of any acute care cardiovascular product to date. Mr. Mahaffey also worked in various marketing functions at Neurex, Inc. (acquired by Elan Corp. for \$700M in 1998). He began his pharmaceutical career at DuPont Pharmaceuticals where he held various sales and marketing positions. Mr. Mahaffey earned a Bachelor of Science degree in Chemical Engineering from the University of Delaware and an MBA from the University of South Florida.



Susan Knudson
CFO

Susan A. Knudson has served as Chief Financial Officer of Neothetics since July 2014 and Vice President of Finance and Administration since February 2009. Ms. Knudson brings over 18 years of financial, venture capital, corporate strategy, and operations experience in the life sciences industry to Neothetics. She has worked in both public and private companies, with operations ranging from domestic to international. Prior to joining Neothetics, Susan served as the Sr. Director of Finance and Administration at Avera Pharmaceuticals, where she spearheaded the Company's financing strategy, raising over \$90 million in venture capital, and was an integral part of the in-licensing of the Company's lead drug candidates from large, multinational pharmaceutical companies. From October 2000 through April 2002, Susan served as Director of Finance and Administration at MD Edge. Ms. Knudson has also held senior positions at Isis Pharmaceuticals and CombiChem. While at CombiChem, she contributed to the Company's successful initial public offering and, later, sale to DuPont. Ms. Knudson holds a B.A. in Accounting from the University of San Diego.

Kim P. Kamdar
Director

Kim P. Kamdar, Ph.D. has served as a member of our board of directors since April 2011. Dr. Kamdar is a managing member of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005. Prior to joining Domain, Dr. Kamdar served as a Kauffman Fellow with MPM Capital. Prior to joining MPM Capital, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Dr. Kamdar currently serves on the board of directors of several private companies, including Ariosa Diagnostics, Epic Sciences, Inc., Obalon Therapeutics, ROX Medical, Sera Prognostics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. Dr. Kamdar received her B.A. in genetics and cell biology from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.



Kenneth W. Locke
Chief Scientific Officer

Kenneth W. Locke serves as our Chief Scientific Officer with over 24 years of experience in the pharmaceutical industry. Concurrent to his service at Neothetics in May 2008, Dr. Locke progressively held the positions of Vice President, Research, Senior Vice President, Development Operations & Drug Discovery, Senior Vice President, Portfolio Management, Chief Business Officer and Chief Scientific Officer with MediciNova, Inc. starting in September 2000. Prior to joining MediciNova, he held the position of Vice President of Research at Tanabe Research Laboratories U.S.A., Inc. From July 2000 to October 2002 Dr. Locke joined Interneuron Pharmaceuticals, Inc. in 1989 as the Manager of Behavioral Neuroscience, taking on positions of increasing responsibility over the next 11 years. Earlier in his career, Dr. Locke headed laboratories for analgesic and anti-inflammatory drug research as well as Alzheimer's disease drug research at Hoechst-Roussel Pharmaceuticals, Inc. Dr. Locke earned a B.A. in Chemistry and French from Franklin and Marshall College and a M.S. and a Ph.D. in Pharmacology from the Emory University School of Medicine.

Board and Management (continued)



Lincoln Krochmal
Chief Medical Officer

Dr. Krochmal is a Board certified Dermatologist with 30 plus years experience in the pharmaceutical and consumer goods industries focusing on the development of new products both locally and globally. His most recent role was as CEO & President of Excaliard Pharmaceuticals. He successfully led the Excaliard team in generating positive Proof of Concept data for their lead compound as a treatment for reducing skin scarring. This data subsequently resulted in Pfizer acquiring Excaliard for a total value close to \$500m. Prior to that he was Executive Vice President, Research and Product Development for Connetics Corporation, a specialty dermatology company headquartered in Palo Alto. Following 3 and a half years with Connetics, Dr Krochmal formed his own consultant business providing strategic guidance and technical assistance to the pharmaceutical and aesthetics industries. Dr. Krochmal began his career in the pharmaceutical industry following 8 years of private dermatology practice by joining Westwood Pharmaceuticals (the dermatology subsidiary of Bristol-Myers Squibb) in 1983 as Director of Clinical Research. Over the subsequent 10 years, he held several roles of increasing responsibility including VP, Dermatology Research and Development, overseeing both preclinical and clinical disciplines, and VP, Worldwide Medical Development, providing global support in Biostatistics & Data Management, Human Pharmacology, Drug Safety, Medical Communications and Clinical Study Field Operations to all 5 Therapeutic Areas of Bristol-Myers Squibb. In 1993, Dr. Krochmal joined Unilever PLC, where he spent 10 years in various senior management positions directing the worldwide development of numerous consumer products for the Home and Personal Care Division.

Chris Kemmerer
Vice President-Pharmaceutical Development and Manufacturing

Chris Kemmerer, Ph.D. serves as our Vice President of Pharmaceutical Development and Manufacturing with 20 years of experience in the pharmaceutical industry. In this capacity, Chris is primarily responsible for developing our drug product formulations and providing pre-clinical and clinical supplies. Prior to joining Neothetics, Chris held the position of Director of Pharmaceutical Development at Avera Pharmaceuticals developing controlled release formulations and formulations of poorly water-soluble drug candidates. Prior to Avera, Chris held positions of increasing responsibility at Pfizer, Inc, La Jolla, CA and was responsible for process and development activities for Diabetes drug candidates. Prior to joining Pfizer, Inc. Chris held positions across numerous functional areas of drug development at Merck & Company in West Point, PA, including in process and formulation development, scale-up, and manufacturing roles. In these capacities, Chris was an important contributor to the development of Emend and oversaw the manufacturing of over 20 commercial drug products including Pepcid, Prilosec, and Nexium. Chris earned a B.S. in Chemistry from Pennsylvania State University and a Ph.D. in Pharmaceuticals Sciences from Temple University in Philadelphia, PA.

Glossary

Capital Gain/Loss from n Years Ago to n-1 Years Ago:

Capital Gain or Loss over 1 Year/Price 1 Year Ago (%)

PVUS\$1000 (Fig 10):

Present value of US\$1000 invested 1 year/'n' years ago

Relative Price Change (Fig 12):

Today's Relative price change with respect to Benchmark Index

Turnover (Fig 5):

Last Price * Volume

Turnover Rate (Fig 4):

US Dollar value of annual trading volume as a percentage of market capitalisation

Volume Index (Fig 5):

Number of shares traded in the period/Average number of shares traded for the period

Moving Average Price (n periods) (Fig 8):

Sum of Prices for each Period/Number of Periods

Price Close/Moving Avg Price (Fig 8):

Latest Price/Moving Average Price

Relative Strength (n-th Period) (Fig 1, 7, 3):

Price close today/Price close 'n' periods ago, then ranked by percentile within the entire market.

Turnover Period (Fig 4):

Time Period required for trading all Outstanding Shares

Volatility (Fig 12):

Highest Price minus Lowest Price/Lowest Price (%)

Volume Weighted Price (VWP) (Fig 12):

The Volume Weighted Price (VWP) is the summation of turnover divided by total volume in the same period.

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

For further details on definitions and quotations from investing legends, [Click here](#)

For any enquiries, please email: feedback@buysellsignals.com

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate.

The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.